Nulibry® (fosdenopterin) Managed Access Program

Nulibry® is approved by the US Food and Drug Administration (FDA) for patients with molybdenum cofactor deficiency (MoCD) Type A. Nulibry is only commercially available in the US at this time. Nulibry is available outside of the US via an Early Access Program for patients who meet specific criteria. An Early Access Program is a compliance mechanism through which a healthcare professional can request a medicine that is not commercially available in their country of residence for patients who have serious illnesses, have no alternative treatment options, and who cannot enroll in a clinical trial for treatment. The Nulibry Early Access Program is being managed by Sciensus. Sciensus can only consider requests for access to Nulibry from qualified healthcare professionals; requests for early access to Nulibry for patients outside of the US should be directed to Sciensus at

For doctors to enroll their patients in this program, please email Sciensus at or call +49 6201 7994408.


Zokinvy® (lonafarnib) Managed Access Program

Sentynl Therapeutics, Inc., manufacturer of Zokinvy® (lonafarnib), provides a Managed Access Program (MAP). MAP allows eligible patients with Hutchinson-Gilford Progeria Syndrome (HGPS) or processing-deficient Progeroid Laminopathies (PDPL) to obtain lonafarnib through their local physicians in countries that allow MAP to be offered and in which Zokinvy is not commercially available.

For doctors to enroll their patients in this program, please email Clinigen’s Medicine Access team at or call +44 (0) 1932 824123.